April 2013 The chief of NIDA's Services Research Branch talks about drug abuse treatment within the criminal justice system, and assesses the challenges facing drug abuse treatment overall in the United States.
July 2012 Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.
July 2012 Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.
July 2011 Describes results from a nationwide survey among correctional facilities on the use of opioid replacement therapy for people who are addicted to heroin.
December 2010 Reports findings from a survey that revealed that although substance abuse is prevalent in jails and prisons, many correctional facilities do not offer detoxification services or therapies to aid in maintaining abstinence.
November 2009 Describes research on the effectiveness of a buprenorphine patch to alleviate opioid withdrawal symptoms of newly abstinent heroin abusers.
October 2006 Reports on a study of adolescents addicted to opioids who responded better to buprenorphine than clonidine in a clinical trial in which all patients also received behavioral therapy.
October 2006 Presents highlights of a study suggesting that compared with methadone, office-based buprenorphine treatment attracts individuals who have less extensive addiction histories.